| Literature DB >> 33650324 |
Zefeng Cai1, Zekai Chen1, Wei Fang1, Weijian Li1, Zegui Huang1, Xianxuan Wang1, Guanzhi Chen2, Weiqiang Wu3, Zhichao Chen3, Shouling Wu4, Youren Chen3.
Abstract
AIMS/Entities:
Keywords: Diabetes; Triglyceride to high-density lipoprotein cholesterol ratio; Variability
Mesh:
Substances:
Year: 2021 PMID: 33650324 PMCID: PMC8504899 DOI: 10.1111/jdi.13536
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Baseline characteristics of the participants in 2010–2011
| Variable | Total | Tertile 1 | Tertile 2 | Tertile 3 |
|
|---|---|---|---|---|---|
|
|
|
|
|
| – |
| Age (years) | 52.37 ± 12.03 | 53.17 ± 12.42 | 52.50 ± 12.15 | 51.43 ± 11.42 | <0.001 |
| Male (%) | 34776 (75.75) | 10854 (70.84) | 11519 (75.23) | 12403 (81.18) | <0.001 |
| BMI (kg/m2) | 24.82 ± 3.11 | 24.06 ± 3.06 | 24.78 ± 3.06 | 25.63 ± 3.00 | <0.001 |
| SBP (mmHg) | 128.35 ± 16.68 | 126.45 ± 17.00 | 128.13 ± 16.64 | 130.49 ± 16.15 | <0.001 |
| DBP (mmHg) | 83.20 ± 9.19 | 81.69 ± 9.12 | 83.04 ± 9.10 | 84.88 ± 9.06 | <0.001 |
| FBG (mmol/L) | 5.15 ± 0.47 | 5.10 ± 0.46 | 5.15 ± 0.46 | 5.20 ± 0.47 | <0.001 |
| Triglyceride (mmol/L) | 1.30 (0.96–1.87) | 0.95 (0.74–1.24) | 1.24 (1.00–1.57) | 2.04 (1.51–2.78) | <0.001 |
| LDL‐C (mmol/L) | 2.49 ± 0.63 | 2.44 ± 0.63 | 2.52 ± 0.61 | 2.50 ± 0.64 | <0.001 |
| HDL‐C (mmol/L) | 1.54 ± 0.32 | 1.64 ± 0.31 | 1.54 ± 0.30 | 1.44 ± 0.31 | <0.001 |
| TG/HDL‐C in 2006 | 0.82 (0.55–1.30) | 0.61 (0.43–0.83) | 0.81 (0.58–1.15) | 1.34 (0.81–2.22) | <0.001 |
| TG/HDL‐C in 2008 | 0.88 (0.56–1.30) | 0.60 (0.43–0.85) | 0.89 (0.62–1.13) | 1.41 (0.91–2.22) | <0.001 |
| TG/HDL‐C in 2010 | 0.84 (0.55–1.33) | 0.60 (0.41–0.83) | 0.85 (0.58–1.20) | 1.39 (0.84–2.28) | <0.001 |
| Mean TG/HDL‐C | 0.89 (0.62–1.35) | 0.59 (0.44–0.82) | 0.84 (0.66–1.09) | 1.51 (1.11–2.12) | <0.001 |
| TG/HDL‐change slope | 0.00 (−0.14–0.17) | –0.01 (−0.09–0.08) | 0.01 (−0.18–0.21) | 0.04 (−0.38–0.50) | <0.001 |
| FBG‐ARV | 0.47 (0.29–0.72) | 0.46 (0.28–0.70) | 0.47 (0.29–0.72) | 0.49 (0.30–0.75) | <0.001 |
| Physical exercise, | 6,540 (14.25) | 2,259 (14.74) | 2,213 (14.46) | 2,068 (13.54) | 0.007 |
| Current smoker, | 15,645 (34.08) | 4,613 (30.11) | 5,132 (33.52) | 5,900 (38.62) | <0.001 |
| Current drinker, | 16,246 (35.39) | 4,838 (31.58) | 5,223 (34.12) | 6,185 (40.49) | <0.001 |
| Family history of diabetes, | 1,462 (3.18) | 443 (2.89) | 447 (3.12) | 542 (3.55) | 0.004 |
| Hypertension, | 19,704 (42.94) | 5,803 (37.90) | 6,420 (41.95) | 7,481 (48.94) | <0.001 |
| Lipid‐lowering drugs therapy, | 375 (0.82) | 60 (0.39) | 104 (0.68) | 211 (1.38) | <0.001 |
Continuous variables are described by mean ± standard deviation (normal distribution)/median (quartile) (abnormal distribution); categorical variables are presented by number (percentage). Tertile 1: triglyceride to high‐density lipoprotein cholesterol ratio average real variability (TG/HDL‐ARV) ≤0.23, tertile 2: 0.23 < TG/HDL‐ARV ≤ 0.52, tertile 3: TG/HDL‐ARV >0.52.
BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL‐C, high‐density lipoprotein‐cholesterol; LDL‐C, low‐density lipoprotein‐cholesterol; SBP, systolic blood pressure.
Figure 1Cumulative incidence of diabetes mellitus in the triglyceride to high‐density lipoprotein cholesterol ratio average real variability (TG/HDL‐ARV) tertile groups.
Risk of incident diabetes according to triglyceride to high‐density lipoprotein cholesterol ratio average real variability
| No. events | Per 1,000 person–years | Model 1 | Model 2 | Model 3 | |
|---|---|---|---|---|---|
| Tertile 1 | 859 | 8.91 | 1 | 1 | 1 |
| Tertile 2 | 1,144 | 11.96 | 1.37 (1.26–1.50) | 1.16 (1.06–1.27) | 1.16 (1.06–1.26) |
| Tertile 3 | 1,721 | 18.20 | 2.11 (1.94–2.29) | 1.38 (1.26–1.51) | 1.37 (1.25–1.50) |
| 1–SD increase (1.33) | 1.06 (1.05–1.07) | 1.04 (1.03–1.06) | 1.04 (1.03–1.06) | ||
|
| <0.001 | <0.001 | <0.001 |
Model 1 was adjusted for age and sex. Model 2 was further adjusted for body mass index, glucose, low‐density lipoprotein‐cholesterol, mean triglyceride to high‐density lipoprotein cholesterol ratio, triglyceride to high‐density lipoprotein cholesterol ratio change slope, physical exercise, smoking status, alcohol consumption, family history of diabetes, hypertension, and the use of lipid‐lowering drugs. Model 3 was further adjusted for glucose variability.
SD, standard deviation.
Figure 2Spline graphical representation of the correlation between triglyceride to high‐density lipoprotein cholesterol ratio variability and incident diabetes in the multivariable‐adjusted model (model 3). TG/HDL‐ARV, triglyceride to high‐density lipoprotein cholesterol ratio average real variability.
Risk of incident diabetes according to triglyceride to high‐density lipoprotein cholesterol ratio average real variability
| Subgroup | Model 1 | Model 2 | Model 3 |
|---|---|---|---|
|
TG/HDL‐change slope >0 ( | |||
| Tertile 1 | 1 | 1 | 1 |
| Tertile 2 | 1.41 (1.24–1.61) | 1.23 (1.08–1.40) | 1.23 (1.09–1.40) |
| Tertile 3 | 2.10 (1.87–2.37) | 1.42 (1.25–1.62) | 1.43 (1.25–1.62) |
|
| <0.001 | <0.001 | <0.001 |
|
TG/HDL‐change slope ≤0 ( | |||
| Tertile 1 | 1 | 1 | 1 |
| Tertile 2 | 1.34 (1.18–1.52) | 1.09 (0.96–1.24) | 1.08 (0.96–1.23) |
| Tertile 3 | 2.12 (1.89–2.38) | 1.32 (1.16–1.49) | 1.29 (1.14–1.47) |
|
| <0.001 | <0.001 | <0.001 |
| Ideal FBG ( | |||
| Tertile 1 | 1 | 1 | 1 |
| Tertile 2 | 1.40 (1.22–1.60) | 1.18 (1.03–1.35) | 1.17 (1.02–1.34) |
| Tertile 3 | 2.17 (1.92–2.47) | 1.46 (1.27–1.67) | 1.43 (1.25–1.65) |
|
| <0.001 | <0.001 | <0.001 |
| Prediabetes ( | |||
| Tertile 1 | 1 | 1 | 1 |
| Tertile 2 | 1.27 (1.13–1.43) | 1.13 (1.01–1.27) | 1.14 (1.01–1.28) |
| Tertile 3 | 1.77 (1.59–1.98) | 1.31 (1.16–1.47) | 1.31 (1.17–1.48) |
|
| <0.001 | <0.001 | <0.001 |
Model 1 was adjusted for age and sex. Model 2 was further adjusted for body mass index, glucose, low‐density lipoprotein‐cholesterol, mean triglyceride to high‐density lipoprotein cholesterol ratio (TG/HDL), TG/HDL‐change slope, physical exercise, smoking status, alcohol consumption, family history of diabetes, hypertension and the use of lipid‐lowering drugs. Model 3 was further adjusted for glucose variability (ARV).
* P for the interaction of TG/HDL‐ARV and TG/HDL‐change slope was 0.011.